Related Links
ARALAST NP AATmosphere Program
Support for Alphas and families from the ARALAST NP AATmosphere program.
ARALAST NP Therapy Safety Profile
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)] is prepared from large pools of human plasma by using the cold ethanol fractionation process followed by purification steps including polyethylene glycol and zinc chloride precipitations and ion exchange chromatography. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Please refer to the Important Risk Information link below for more detailed risk information.
ARALAST NP therapy has a multi-step purification process that includes two viral treatment steps:
- Solvent Detergent Treatment rapidly inactivates lipid-enveloped viruses such as HIV and Hepatitis B and C.
- Nanofiltration reduces the risk of transmission of non-lipid-enveloped viral agents.
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the Important Risk Information and the Full Prescribing Information
Please review the Important Risk Information and the Full Prescribing Information
